Science

Our Science

At Lxbio Phar­ma­ceu­ti­cals, we are com­mit­ted to dis­cov­er bio­phar­ma­ceu­ti­cal solu­tions that aim to trans­form health­care and improve patient lives.

Our port­fo­lio encom­pass­es a range of inno­v­a­tive ther­a­pies devel­oped through advanced biotech­no­log­i­cal process­es. 

Con­tact Us

Bacteriophages Technology1

Bac­te­rio­phages are virus­es that can lyse the bac­te­ria they infect. Bac­te­rio­phages can be used alone or in com­bi­na­tion with oth­er antimi­cro­bials to improve their effi­ca­cy.

The tech­nol­o­gy involves nat­u­ral­ly occur­ring and genet­i­cal­ly mod­i­fied phages com­bined in a cock­tail of lyt­ic bac­te­rio­phages to specif­i­cal­ly tar­get the bac­te­ria caus­ing the infec­tions, which means that each phage has only a spe­cif­ic host tar­get.

The tech­nol­o­gy com­bines bac­te­rio­phages mixed as cock­tails to broad­en their prop­er­ties result­ing in a col­lec­tive­ly greater antibac­te­r­i­al spec­trum of  activ­i­ty.

An alter­na­tive to anti­biotics in the age of mul­ti-drug resis­tance.

Phages infect and kill bac­te­ria at the site of infec­tion.

A phage will kill a bac­teri­um only if it match­es the spe­cif­ic strain.

Phages are natural predators of bacteria

Phages are virus­es con­sist­ing of a genome enclosed with­in a pro­tein cap­sid that infects bac­te­ria.

They tar­get the dan­ger­ous microbes with­out harm­ing human cells, due to how spe­cif­ic they are. 

They are the most com­mon bio­log­i­cal enti­ties in nature and have been shown to effec­tive­ly fight and destroy mul­ti-drug resis­tant bac­te­ria. Name­ly, when all antibi­otics fail, phages may still suc­ceed in killing the bac­te­ria and may save a life from an infec­tion.

They are made of pro­teins that encap­su­late a DNA or RNA genome with as few as 4 genes and as many as hun­dreds, in the top sec­tion. 

Most phages can be clas­si­fied as being lyt­ic or tem­per­ate. Lyt­ic phages kill a very high pro­por­tion of bac­te­r­i­al cells they infect and there­fore are suit­able for ther­a­peu­tic con­sid­er­a­tion.

Phage-based Delivery Systems2

Based on a mod­u­lar archi­tec­ture built on a bac­te­rio­phage fil­a­men­tous, the plat­form LXON01 is a next-gen­er­a­tion tar­get­ed can­cer ther­a­py built using an engi­neered M13 bac­te­rio­phage nanopar­ti­cle.

This nanoscale plat­form acts as a pro­gram­ma­ble bio­log­i­cal car­ri­er capa­ble of deliv­er­ing tar­get­ing mol­e­cules, cyto­tox­ic drugs, and immune-stim­u­lat­ing sig­nals simul­ta­ne­ous­ly with­in a sin­gle ther­a­peu­tic sys­tem. The par­ti­cle was designed with three com­ple­men­tary func­tions.

First, a HER2-tar­get­ing anti­body frag­ment directs the par­ti­cle to tumour cells that over­ex­press the HER2 recep­tor, pro­mot­ing selec­tive bind­ing and inter­nal­i­sa­tion.

Sec­ond, the phage sur­face could car­ry mul­ti­ple mol­e­cules, enabling high-den­si­ty drug deliv­ery direct­ly inside can­cer cells.

Third , immune-acti­vat­ing cytokines dis­played on the par­ti­cle help stim­u­late local immune respons­es with­in the tumour microen­vi­ron­ment. By com­bin­ing pre­ci­sion tar­get­ing, high-pay­load drug deliv­ery, and immune acti­va­tion, LXON01 was designed to attack sol­id tumours through mul­ti­ple com­ple­men­tary mech­a­nisms. This inte­grat­ed approach aims to enhance anti-tumour effi­ca­cy while focus­ing activ­i­ty at the tumour site, pro­vid­ing a new strat­e­gy for treat­ing HER2-pos­i­tive can­cers resis­tant to cur­rent ther­a­pies.

Engineering Breakthrough Biopharmaceuticals3

Our Anti­body frag­ments, such as Fab, scFv (sin­gle-chain vari­able frag­ments), and nanobod­ies, rep­re­sent a cut­ting-edge break­through in bio­phar­ma­ceu­ti­cal inno­va­tion. These engi­neered mol­e­cules are small­er, more ver­sa­tile ver­sions of full anti­bod­ies, designed to enhance treat­ment pre­ci­sion and effi­ca­cy in com­plex fields like oncol­o­gy, oph­thal­mol­o­gy and der­ma­tol­ogy.

In Oph­thal­mol­o­gy, Anti­body frag­ments, par­tic­u­lar­ly Fab frag­ments, have trans­formed the treat­ment of eye dis­eases. A Fab frag­ment, tar­gets VEGF to pre­vent abnor­mal blood ves­sel growth in con­di­tions like age-relat­ed mac­u­lar degener­ation (AMD) and dia­bet­ic retinopa­thy. These frag­ments are designed for supe­ri­or pen­e­tra­tion into ocu­lar tis­sues, deliv­er­ing tar­get­ed action with few­er sys­temic side effects, mak­ing them a crit­i­cal tool in pre­serv­ing and resto­ring vision.

In Der­ma­tol­ogy, anti­body frag­ments offer tar­get­ed solu­tions for inflam­ma­to­ry skin dis­eases and can­cers. Nano­bodies and scFv frag­ments, due to their small size and high speci­fici­ty, are being engi­neered to treat con­di­tions like pso­riasis and atopic der­mati­tis. These frag­ments can be devel­oped for both sys­temic and top­i­cal ther­a­pies, offer­ing tai­lored treat­ments with reduced adverse effects.

Nanoparticles Technology4

Nan­otech­nol­o­gy is rev­o­lu­tion­iz­ing oph­thalmic med­i­cine by enabling the devel­op­ment of nanopar­ti­cle- ased drug deliv­ery sys­tems, espe­cial­ly in the form of eye drops. These nanoscale par­ti­cles, typ­i­cal­ly rang­ing from 1 to 100 nanome­ters, are engi­neered to improve drug absorp­tion, sta­bil­i­ty, and tar­get­ed deliv­ery, over­com­ing the nat­ur­al bar­ri­ers of the eye.

 

Nanoparticles Technology

Nanoparticles advantages:

  • 1. Improved drug pen­e­tra­tion
  • 2. Increased sol­u­bil­i­ty
  • 3. Sus­tained drug release
  • 4. Pro­longed drug reten­tion time
  • 5. Improved effi­ca­cy
  • 6. Reduced tox­i­c­i­ty

A major step for­ward in patient com­fort, com­pli­ance, and safe­ty.

Of utmost impor­tance, the nanopar­ti­cle may be used top­i­cal­ly, in eye­drops for­mu­la­tion, whitch can effec­tive­ly treat dis­eases, such as age relat­ed mac­u­lar degen­er­a­tion (AMD), dia­bet­ic retinopa­thy (DR) and dia­bet­ic mac­u­lar ede­ma (DME), thus elim­i­nat­ing the need for inva­sive intrav­it­re­al injec­tions.

Source

1 – Pires, D. P., Melo, L. D. R., Vilas Boas, D., Sil­lan­korva, S., & Aze­redo, J. (2017). Phage the­rapy as an al­ter­na­tive or com­ple­men­tary stra­tegy to pre­vent and con­trol bio­­film-re­la­t­ed in­fec­tions. Cur­rent Opi­nion in Mi­cro­bio­lo­gy, 39, 48–56. 

2 – Chang, C., Guo, W., Yu, X., Guo, C., Zhou, N., Guo, X., Huang, R.-L., Li, Q., & Zhu, Y. (2023). En­gi­neered M13 phage as a no­vel the­ra­peu­tic bio­na­no­ma­te­rial for cli­ni­cal ap­pli­ca­tions: From tis­sue re­ge­ne­ra­tion to can­cer the­rapy. Ma­te­rials To­day Bio, 20, 100612. 

3 – Nel­son, A. L. (2010). An­ti­body frag­ments: Hope and hype. mAbs, 2(1), 77–83. 

4 – Li, S., Han, H., Xu, M., Zhang, Y., Liu, Y., & Wang, J. (2023). Na­no­tech­no­lo­­gy-based ocu­lar drug de­li­very sys­tems: Ad­van­ces and fu­ture per­spec­tives. Jour­nal of Na­no­bio­tech­no­lo­gy, 21, 232.